id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0097,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2012-12-17T05:00:00Z,2012,12,2012-12-17T05:00:00Z,2013-02-16T04:59:59Z,2013-02-16T03:01:24Z,2012-30308,0,0,090000648118f5a2
FDA-2007-D-0369-0093,FDA,FDA-2007-D-0369,Guidance for Industry Bioequivalence Recommendations for Specific Products,Other,Guidance,2012-09-21T04:00:00Z,2012,9,2012-09-21T04:00:00Z,,2024-11-12T05:06:22Z,,1,0,0900006481121a18
FDA-2007-D-0369-0092,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Pentosan Polysulfate Sodium Capsule; Availability,Notice,Notice of Data Availability,2012-09-20T04:00:00Z,2012,9,2012-09-20T04:00:00Z,2012-11-20T04:59:59Z,2012-11-19T02:16:02Z,2012-23177,0,0,090000648111feb8
FDA-2007-D-0369-0091,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2012-09-14T04:00:00Z,2012,9,2012-09-14T04:00:00Z,2012-11-14T04:59:59Z,2015-06-13T20:46:53Z,2012-22658,0,0,09000064811171e8
FDA-2007-D-0369-0087,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry; Availability: Describing Product-Specific Bioequivalence Recommendations,Notice,Notice of Availability,2012-06-14T04:00:00Z,2012,6,2012-06-14T04:00:00Z,2012-08-14T03:59:59Z,2015-03-13T04:55:27Z,2012-14477,0,0,0900006481049abd
FDA-2007-D-0369-0088,FDA,FDA-2007-D-0369,Guidance for Industry Toll Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications,Other,Guidance,2012-06-14T04:00:00Z,2012,6,2012-06-14T04:00:00Z,,2015-03-13T04:56:50Z,,0,0,090000648104a3fa
FDA-2007-D-0369-0077,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Iron Sucrose Injection; Availability,Notice,Notice of Availability,2012-03-28T04:00:00Z,2012,3,2012-03-28T04:00:00Z,2012-05-30T03:59:59Z,2012-10-03T21:35:21Z,2012-07456,0,0,0900006480fe2f3c
FDA-2007-D-0369-0078,FDA,FDA-2007-D-0369,Draft Guidance on Iron Sucrose; re on Bioequivalence Recommendations for Iron Sucrose Injection,Other,Guidance,2012-03-28T04:00:00Z,2012,3,2012-03-28T04:00:00Z,,2024-11-12T04:48:25Z,,1,0,0900006480fe32c1
FDA-2007-D-0369-0076,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Availability: Product-Specific Bioequivalence Recommendations,Notice,Notice of Data Availability,2012-03-22T04:00:00Z,2012,3,2012-03-22T04:00:00Z,2012-05-22T03:59:59Z,2015-03-13T04:53:48Z,2012-06947,0,0,0900006480fddaca
FDA-2007-D-0369-0075,FDA,FDA-2007-D-0369,Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2012-02-22T05:00:00Z,2012,2,2012-02-22T05:00:00Z,,2015-03-13T04:52:46Z,2012-04037,0,0,0900006480fbd6aa
FDA-2007-D-0369-0074,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2012-02-22T05:00:00Z,2012,2,2012-02-22T05:00:00Z,,2024-01-30T02:00:18Z,2012-04035,0,0,0900006480fbd63d
FDA-2007-D-0369-0072,FDA,FDA-2007-D-0369,Draft Guidance on Nitroglycerin; Guidance Document,Other,Guidance,2012-02-13T05:00:00Z,2012,2,2012-02-13T05:00:00Z,,2024-11-07T22:27:06Z,,1,0,0900006480fb4910
FDA-2007-D-0369-0070,FDA,FDA-2007-D-0369,"Draft Guidance for Industry on Bioequivalence Recommendation for
Nitroglycerin Metered Spray/ Sublingual Products and Metered
Aerosol/Sublingual Products; Availability",Notice,Notice of Availability,2012-02-13T05:00:00Z,2012,2,2012-02-13T05:00:00Z,2012-04-14T03:59:59Z,2015-03-13T05:13:39Z,2012-03233,0,0,0900006480fb40eb
FDA-2007-D-0369-0069,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Availability: Bioequivalence Recommendations for Rifaximin Tablets,Notice,Notice of Availability,2012-02-13T05:00:00Z,2012,2,2012-02-13T05:00:00Z,2012-04-14T03:59:59Z,2012-02-13T16:12:13Z,2012-03234,0,0,0900006480fb4000
FDA-2007-D-0369-0073,FDA,FDA-2007-D-0369,Draft Guidance on Nitroglycerin; Guidance Document,Other,Guidance,2012-02-13T05:00:00Z,2012,2,2012-02-13T05:00:00Z,,2024-11-12T05:01:38Z,,1,0,0900006480fb4911
FDA-2007-D-0369-0071,FDA,FDA-2007-D-0369,Draft Guidance on Rifaximin Tablets; Guidance Document,Other,Guidance,2012-02-13T05:00:00Z,2012,2,2012-02-13T05:00:00Z,,2024-11-12T04:25:01Z,,1,0,0900006480fb4907
FDA-2007-D-0369-0067,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Product-Specific Bioequivalence Recommendations,Notice,Notice of Availability,2012-01-25T05:00:00Z,2012,1,2012-01-25T05:00:00Z,,2024-11-07T22:25:43Z,2012-01433,1,0,0900006480fa3bd9
FDA-2007-D-0369-0065,FDA,FDA-2007-D-0369,Guidance for Industry on Bioequivalence Recommendations for Specific Products; Availability - re FDA-2007-D-0433,Notice,Notice of Availability,2012-01-17T05:00:00Z,2012,1,2012-01-17T05:00:00Z,,2019-08-06T14:36:42Z,2010-14036,0,0,0900006480f985ef